Search clinical trials for: Nilotinib, Imatinib

Total 4240 results

Qilu Hospital of Shandong University

Unknown

Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer (TCL-1)

Non-Small-Cell Lung Cancer

China
Institut Bergonié
Novartis

Terminated

Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response (MIM)

Leukemia, Myeloid, Chronic-Phase

France
University Health Network, Toronto
Novartis

Terminated

A Study of Nilotinib in Growing Vestibular Schwannomas

Growing Vestibular Schwannomas

Canada
Novartis Pharmaceuticals

Completed

CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib (MACS1428)

Chronic Myelogenous Leukemia in Chronic Phase

United States
Assistance Publique - Hôpitaux de Paris

Unknown

Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas. (NILOMEL)

Stage IV Melanoma | Stage III Melanoma | Amplification | Malignant Skin Melanoma T0

France
PETHEMA Foundation

Recruiting

Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE

Acute Lymphoblastic Leukemia Ph Positive

Spain
Yonsei University

Completed

A Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis)

Fibromatosis

Korea, Republic of
St. Justine's Hospital

Terminated

Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas

Plexiform Neurofibromas

Canada
Cttq
Ruijin Hospital

Unknown

Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia

Chronic Myeloid Leukemia
Novartis

Completed

Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)

Chronic Myelogenous Leukemia in Chronic Phase
Novartis

Completed

Effects of Imatinib in Subjects With Seasonal Allergic Rhinitis and Who Are Sensitive to Timothy Grass Pollen

Seasonal Allergic Rhinitis

United Kingdom
Seoul St. Mary's Hospital
Novartis

Unknown

Prospective Investigation of Dynamics of ABL Mutations in Imatinib Failed CML Patients Treated With Nilotinib (AMICAN)

Chronic Myeloid Leukemia

Korea, Republic of
Instituto Nacional de Cancerologia de Mexico

Unknown

Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma

EGFR Gene Mutation | Tyrosine Kinase Mutation | Non-Small Cell Adenocarcinoma

Mexico
Asan Medical Center

Active, not recruiting

Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI

Gastrointestinal Stromal Tumors

Korea, Republic of
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib (CML0609)

Chronic Myeloid Leukaemia

Italy
Centre Oscar Lambret
Novartis; National Cancer Institute, France

Terminated

Imatinib in Adult Patients With Metastatic Ocular Melanoma (O-Mel-Inib)

Melanoma

France
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

STI 571 (GLIVEC) in the Treatment of Adult Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

Italy
Azienda Ospedaliera Universitaria Policlinico
Università Politecnica delle Marche

Unknown

Low-Dose Oral Imatinib for Scleroderma Pulmonary Involvement

Systemic Sclerosis

Italy
Central European Leukemia Study Group

Unknown

Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase

Chronic Myeloid Leukemia

Austria
Emory University

Terminated

Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia

Leukemia | Chronic Myeloid Leukemia | Chronic Myelogenous Leukemia

United States
M.D. Anderson Cancer Center
Novartis

Completed

PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP

Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Agnogenic Myeloid Metaplasia

United States
Samsung Medical Center

Active, not recruiting

Patients With Refractory, Metastatic Cancer Harboring KIT Mutation or Amplification to Investigate the Clinical Efficacy and Safety of Imatinib Therapy

Advanced, Refractory Cancer

Korea, Republic of
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Imatinib in Chordoma

Chordoma

Switzerland, Italy
Novartis Pharmaceuticals

Completed

A Prospective, Multicenter Study on Best Clinical Use of Imatinib in the Advanced Gastrointestinal Stromal Tumors

Advanced Gastrointestinal Stromal Tumors

Italy
Gustave Roussy, Cancer Campus, Grand Paris

Unknown

Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck

Carcinoma, Adenoid Cystic | Cancer of the Head and Neck

France
Hospices Civils de Lyon

Unknown

Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly With Imatinib Mesylate (STI571) and Chemotherapy.

Acute Lymphocytic Leukemia

France
Novartis Pharmaceuticals

Completed

Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate (Radix)

Progressive Gastrointestinal Stromal Tumor

Germany
Stanford University

Completed

Imatinib in Systemic Sclerosis

Scleroderma, Systemic

United States
Heidelberg University
Novartis

Completed

Study to Evaluate Imatinib in Desmoid Tumors

Desmoid Tumor | Aggressive Fibromatosis

Germany
Novartis Pharmaceuticals

Completed

Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

Life Threatening Diseases
UNICANCER

Completed

Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis

Desmoid Tumor

France
University of Michigan Rogel Cancer Center

Terminated

Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma

Thyroid Cancer

United States
University Hospital, Bordeaux

Completed

Evaluation of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia (STIM)

Myeloid Leukemia, Chronic

France
University Hospital, Bordeaux
Novartis; Ministry of Health, France

Completed

Efficacy and Safety of Imatinib in Scleroderma (SCLEROGLIVEC)

Scleroderma, Systemic | Scleroderma, Localized

France
Maisonneuve-Rosemont Hospital
Hippocrate Research & Development

Unknown

Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST)

Gastrointestinal Stromal Tumors

Canada
National Taiwan University Hospital

Completed

Nilotinib for Cytomegalovirus Prophylaxis and Treatment After Allogeneic Hematopoietic Stem Cell Transplantation

Patients Who Have Received Allo-HSCT

Taiwan
Georgetown University

Completed

Nilotinib in Cognitively Impaired Parkinson Disease Patients 001

Parkinson's Disease | Parkinson's Disease Dementia | Diffuse Lewy Body Disease

United States
Jill M Kolesar
National Cancer Institute (NCI); Novartis

Recruiting

Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma

Metastatic Melanoma | BRAF Gene Mutation

United States
Betta Pharmaceuticals Co., Ltd.

Unknown

Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC

Adenocarcinoma | EGFR Positive Non-small Cell Lung Cancer

China
M.D. Anderson Cancer Center

Completed

Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia

Chronic Myelogenous Leukemia

United States
Novartis Pharmaceuticals

Completed

Nilotinib for Patients With Chronic Myeloid Leukemia in First Line and Any Subsequent Line (NOFRETETE)

Chronic Myeloid Leukemia

Germany
Hospital for Special Surgery, New York
Novartis Pharmaceuticals; Rudolph Rupert Scleroderma Program

Completed

Nilotinib in the Treatment of Systemic Sclerosis

Systemic Sclerosis

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetics of Nilotinib in Subjects With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function

Healthy

United States
Novartis Pharmaceuticals

Completed

An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment (MACS0999)

Chronic Myelogenous Leukemia

United States, Canada
National Taiwan University Hospital
National Cheng-Kung University Hospital; Far Eastern Memorial Hospital; Tri-Service... and other collaborators

Terminated

Imatinib for Cytomegalovirus Prophylaxis and Treatment After Allogeneic Hematopoietic Stem Cell Transplantation

Patients Who Have Received Allo-HSCT

Taiwan
European Organisation for Research and Treatment...
UNICANCER; Grupo Espanol de Investigacion en Sarcomas; Italian Sarcoma Group

Completed

Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumor

France, Australia, United Kingdom, Germany, Denmark, Spain
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma

Brain and Central Nervous System Tumors

United States
Professor Mikael Svensson, MD PhD

Unknown

Treatment of Cervical Spinal Cord Injury With Imatinib - a Safety and Feasibility Study

Cervical Spinal Cord Injury
Shanghai Zhongshan Hospital
Changhai Hospital; Fudan University; Huashan Hospital; Ruijin Hospital; Shanghai...

Unknown

Study to Compare Pathologic Type, NIH and WHO Criteria,and Mechanism of GIST Malignant Transformation

Method of Differentiating Benignancy and Malignancy, Grading and Staging for GIST

China
Dana-Farber Cancer Institute
Novartis

Completed

Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma (BUS255)

Mucosal Melanoma | Acral/Lentiginous Melanoma | Chronically Sun Damaged Melanomas

United States

Search clinical trials for: Nilotinib, Imatinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Serbia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations